Other
Chemoradiation
0
Pipeline Programs↗
8
Active Trials↗
0
Companies Involved↗
Chemoradiation is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
31
clinical trials
Completed13 · 42%
Recruiting7 · 23%
Unknown status5 · 16%
Terminated2 · 6%
Withdrawn2 · 6%
Not yet recruiting1 · 3%
Other1 · 3%
Clinical Trials
Trial Activity
31 trials
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06061146·136 enrolled
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07038629·52 enrolled
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Recruiting·—·Phase 2·NCT05213884·30 enrolled
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait
Recruiting·—·N/A·NCT05000697·216 enrolled
Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
Completed·—·Phase 2·NCT00831181·27 enrolled
Chemoradiation or Brachytherapy for Rectal Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02017704·9 enrolled
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
Completed·—·Phase 2·NCT02343952·93 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)